Intrinsic OXPHOS limitations underlie cellular bioenergetics in leukemia

Area of Science:

• Biochemistry
• Cancer Biology
• Mitochondrial Biology

Background:

• Targeting mitochondrial oxidative phosphorylation (OXPHOS) is a key area in cancer therapy.
• Current mito-therapeutics often lack specificity, leading to a limited therapeutic index.
• Acute myeloid leukemia (AML) presents a model for investigating cancer-specific mitochondrial vulnerabilities.

Purpose of the Study:

• To identify actionable bioenergetic vulnerabilities in cancerous mitochondria using AML as a model.
• To investigate the role of OXPHOS in AML growth, proliferation, and chemoresistance.
• To explore the potential of restoring OXPHOS as a therapeutic strategy for AML.

Main Methods:

• Utilized an in-house diagnostic biochemical workflow to analyze mitochondrial function in AML.
• Performed experiments across a physiological range of ATP free energy to assess mitochondrial ATP consumption.
• Investigated the cytotoxic effects of acute restoration of oxidative ATP synthesis on leukemic cells.

Main Results:

• AML exhibits a hyper-metabolic phenotype with increased respiration but intrinsic OXPHOS limitations.
• Leukemic mitochondria are uniquely poised to consume ATP, not primarily produce it.
• Acute restoration of oxidative ATP synthesis demonstrated high cytotoxicity against leukemic blasts.
• OXPHOS repression appears to support aggressive disease dissemination in AML.

Conclusions:

• Leukemic mitochondria's primary role may not be ATP production, challenging current therapeutic assumptions.
• Restoring, rather than inhibiting, OXPHOS presents a promising therapeutic avenue for hematological malignancies.
• This strategy holds potential for overcoming chemoresistance in AML and other cancers.